Marquette Asset Management Exits Position in Bristol-Myers Squibb Co (BMY)

Bristol-Myers Squibb Co (BMY) : Marquette Asset Management has sold out all of its stake in Bristol-Myers Squibb Co during the most recent quarter, according to the disclosure filed by the company on Apr 13, 2016 with the SEC. The investment management company has sold out 3,100 shares of Bristol-Myers Squibb Co which is valued at $210,955.

Bristol-Myers Squibb Co opened for trading at $68.08 and hit $68.9501 on the upside on Monday, eventually ending the session at $68.86, with a gain of 1.19% or 0.81 points. The heightened volatility saw the trading volume jump to 33,46,257 shares. Company has a market cap of $114,959 M.

Other Hedge Funds, Including , Santa Fe Partners boosted its stake in BMY in the latest quarter, The investment management firm added 24,578 additional shares and now holds a total of 37,114 shares of Bristol-Myers Squibb Co which is valued at $2,525,608. Bristol-Myers Squibb Co makes up approx 0.41% of Santa Fe Partners’s portfolio.Fjarde Ap-fonden Fourth Swedish National Pension Fund boosted its stake in BMY in the latest quarter, The investment management firm added 48,888 additional shares and now holds a total of 379,727 shares of Bristol-Myers Squibb Co which is valued at $25,840,422. Bristol-Myers Squibb Co makes up approx 0.59% of Fjarde Ap-fonden Fourth Swedish National Pension Fund’s portfolio.Edge Wealth Management boosted its stake in BMY in the latest quarter, The investment management firm added 126 additional shares and now holds a total of 965 shares of Bristol-Myers Squibb Co which is valued at $63,671. Bristol-Myers Squibb Co makes up approx 0.03% of Edge Wealth Management’s portfolio.

On the company’s financial health, Bristol-Myers Squibb Co reported $0.38 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $0.28. The company had revenue of $4287.00 million for the quarter, compared to analysts expectations of $4154.19 million. The company’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.46 EPS.

Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Societe Generale Initiated Bristol-Myers Squibb Co on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $48.Bristol-Myers Squibb Co was Upgraded by Berenberg to ” Buy” on Jan 22, 2016.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Leave a Reply

Bristol-Myers Squibb Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bristol-Myers Squibb Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.